Oral squamous cell carcinoma (OSCC) is a lethal disease, with rising incidence. In 2011, 6,767 new cases and 2,056 deaths occurred in the UK. Cancers are preceded by oral potentially malignant disorders (PMD), recognizable mucosal diseases harbouring increased, SCC risk offering clinicians a 'therapeutic window' to intervene. Contemporary practice remains unable to predict lesion behaviour or quantify malignant transformation (MT) risk. No clear management guidelines exist and the literature cannot determine whether early diagnosis and intervention prevents cancer. 773 laser treatments were performed between 1996 and 2014 in Newcastle Maxillofacial Surgery and efficacy of intervention examined by reviewing clinico-pathological details and clinical outcome for 590 PMD patients followed for a mean of 7.3yrs. Histopathology required 'up-grading' in 36% on examining excision specimens. 74.2% of patients were disease free (DF), younger patients with 'lowgrade' dysplasia, whilst 9% exhibited persistent disease and were older with proliferative verrucous leukoplakia (PVL). DF status was less likely for erythroleukoplakia (p=0.022), 'high-grade' dysplasia (p<0.0001) and with lichenoid inflammation (P=0.028). In 12%, unexpected OSCC was identified, whilst 4.8% transformed to malignancy. Interventional laser surgery facilitates definitive diagnosis and treatment, allows early diagnosis of OSCC, identifies progressive disease and defines outcome categories. Evidence is lacking that intervention halts carcinogenesis. Multi-centre, prospective, RCTs are needed to confirm the efficacy of surgery.
Introduction
Oral squamous cell carcinoma (OSCC), probably the commonest head and neck malignancy, remains lethal and deforming due to local invasion, oro-facial destruction, metastasis to cervical lymph nodes and blood-borne tumour dissemination 1 . In 2011, 6,767 new cases and 2,056 deaths occurred in the UK whilst globally OSCC shows rising incidence with prognosis significantly compromised by advanced disease and late presentation 2 . The 'progression model' for oral carcinogenesis proposes that, following irreversible genotypic mutation, phenotypic epithelial disorganisation and dysmaturation changes occur which, if allowed to progress, lead to invasive OSCC 3 . Such features preceding cancer are identifiable microscopically and collectively termed dysplasia 4 .
In clinical practice, assessment of the degree of dysplastic change is made following incision biopsy and classification into mild, moderate or severe categories, according to the extent of atypical epithelium 5 .
It has been recognized for many years that a spectrum of distinct mucosal abnormalities, now termed potentially malignant disorders (PMD) and which accompany dysplasia, may be identified clinically, albeit non-specifically, during oral examination. There is, therefore, opportunity for early diagnosis and therapeutic intervention during this 'oral pre-cancer window' 6 . PMD encompasses primarily localized lesions such as leukoplakia, erythroplakia and erythroleukoplakia, together with progressive multi-focal disorders such as proliferative verrucous leukoplakia (PVL) 7, 8 . PMD identification in a patient does not mean inevitable malignant transformation (MT) will occur. Many lesions do not progress, while others spontaneously resolve, but it remains impossible in clinical practice to predict behaviour for individual cases. Nonetheless, PMD patients remain at increased risk of OSCC 9 .
'Potential malignancy' is difficult to define so it is unsurprising that previous treatment interventions have been non-specific with ill-defined goals and end-points; the few clinical trials in the literature concentrate on medical therapies and are compromised by small patient numbers and short study durations 10 . No study has demonstrated long-term lesion resolution, reduction in disease incidence or prevention of MT 11 . Arduino et al 12 emphasized the need for long term patient studies to improve understanding of PMD natural history.
Lack of insight into PMD progression has resulted in a variety of proposed treatments based upon clinicians' preferences and experience. PMDs are mucosal lesions only so do not require the aggressive treatment necessary for removal or destruction of invasive cancer. It seems self-evident, therefore, to intervene early to excise dysplastic tissue at this 'pre-invasive' stage.
Interventional laser therapies evolved following demonstrable failure of observational and medical treatments and limitations in conventional surgery to treat oral PMD 13, 14, 15, 16, 17 . The use of carbon dioxide (CO 2 ) laser facilitates surgical management, providing precise excision, full histopathological lesion assessment, minimal post-operative morbidity and coordinated patient follow up 14, 17, 18 . Whilst excision is preferred, a limited role for ablation allows a defocused laser beam to destroy small or less dysplastic lesions particularly on gingiva / alveolar sites 16 .
Previous PMD treatment studies are limited by small patient numbers and varying follow up periods. Detailed, long term analysis of a large, well-defined PMD patient cohort undergoing coordinated treatment and follow-up was overdue.
Aims of the Study
In the absence of national PMD disease statistics or a robust evidence-base for treatment, the aims of this study were to profile patient demography and clinicopathological data for a patient cohort presenting to a specialist PMD service in NorthEast England, to determine clinical outcomes following interventional CO 2 laser surgery and to assess treatment efficacy and its influence on the progress of oral carcinogenesis. 3. Histopathology Diagnoses. Incision biopsies were performed under the direction of the first author (PJT) and excision specimens obtained following interventional laser treatment as detailed previously 14 . Laser surgery was carried out by PJT, or by colleagues working under direct supervision, within 6 to 12 weeks following incision biopsy to avoid disease progression. Formalin-fixed tissue specimens were assessed via standardized histopathology examination by oral pathologists at the Royal Victoria Infirmary working to agreed diagnostic criteria with peer review and consensus grading 4 . Using the World Health Organization (WHO) classification, specimens were graded as mild, moderate or severe dysplasia, carcinoma-in-situ (CiS) or OSCC. In addition, presence of hyperkeratosis, lichenoid inflammation (LI), or diagnoses of PVL and chronic hyperplastic candidosis (CHC) were recorded.
Method

Clinical Outcome Categories.
By reviewing case records, the authors assigned patients to one of the following clinical outcome categories: Disease Free (DF), the absence of PMD, Further Disease achieving DF status following additional intervention (Further/DF), Further Disease persisting despite intervention (Further/Persistent) and MT, if OSCC was confirmed by histopathological examination.
Statistical Analyses.
Descriptive Statistics were used to summarise details of patient demography, clinical features and pathological diagnoses, together with documentation of treatment interventions, clinical outcome and follow-up data. Histopathology diagnoses were treated as categorical variables and testing of agreement between incision biopsy and post-laser excision biopsy diagnoses carried out using weighted kappa statistics; a coefficient of 1 represented perfect agreement.
Clinical Outcomes were stratified as DF or Persistent Disease (further PMD or MT); success rates and 95% Confidence Intervals (CI) were calculated. Multivariate logistic regression was used to analyse factors potentially prognostic of DF outcome (age at first treatment, sex, lesion appearance, anatomical site and histopathology data). Relationships between factors were explored using chi-square tests for categorical variables, correlation coefficients or logistic regression to check for collinearity. Factors were first explored univariately and then a multivariate model built using a stepwise procedure until all variables were significant at the 10% level. Candidate variables for the initial model were those significant at the 20% level univariately. If collinearity was suspected only the most significant univariate relationships were included in the model. MT was analysed using univariate Cox regression to investigate clinico-pathological variables that might influence time to transformation. All statistical analyses were performed using SAS/STAT ® 9.3 software (SAS Institute Inc, Cary, USA). Table 1 summarizes the study results. Figure  1 . Univariate Cox regression analysis showed no significant influence of clinicopathological variables on MT time, but this could be due to the small number of events in the analysis.
Results
Discussion
1.
Introduction. This data set of 590 PMD patients, undergoing standardised and coordinated treatment by a single surgeon offers additional insight into the natural history of PMD in North-East England, albeit in a defined hospital population. The study provides detailed outcome data recorded over a follow-up period of 19 years (mean 7.3 years).
Patient Demographics.
Demographics confirmed a median patient age of 60 years and, with 59% of cases male and 41% female, a 1.4:1 male to female ratio. No significant relationships between age/sex and PMD presentation or clinical outcome were characterised which is similar to previous analyses 14, 19, 20 . Most patients regularly smoked tobacco and drank alcohol confirming these as relevant aetiological factors in Northern England 3 .
Clinico-Pathological Features.
The majority of PMD lesions were leukoplakias arising on the floor of mouth and ventro-lateral tongue, consistent with previous observations, probably due to underlying site predisposition to epithelial cell dysregulation and carcinogenic influence 21, 22 . 88.5% of lesions in this study exhibited dysplasia or CiS, emphasizing the 'high-risk' nature of PMD disease in this population 17 . Re-grading of tissue specimens in a research-orientated approach was not undertaken as this would not have reflected the 'real-world' nature of the study 23 .
Whilst the prognostic significance of PMD lesions exhibiting LI (sometimes termed lichenoid dysplasias) has proved controversial 5, 8, 24 , this study has confirmed that persistent PMD disease is associated with lesions exhibiting LI. Previous clinical studies have observed isolated erythroleukoplakic lesions with LI arising at ventrolateral tongue sites to be at 'high risk' of MT 25, 26 . Whilst oral lichenoid lesions have not been routinely followed up continuously, this may be advisable to monitor for early cancerous change 8 .
Laser Treatment.
Whilst the use of CO 2 laser as an effective, low-morbidity PMD treatment modality has been documented previously 14, 16, 17, 19, 20 , this study has facilitated analysis of laser treatment in the largest patient cohort reported in the literature 17, 27 . Advantages of laser include a relatively bloodless surgical field, improved intra-operative accuracy, reduced post-operative pain, limited scarring, reduced damage to adjacent tissues, low complication rates and the ability to repeat treatment 14, 16, 17, 18 . Laser excisions were performed in 89% of patients distinguishing this study from previous publications favouring ablative techniques 28 , the latter disadvantaged by lack of definitive biopsy and repeat application required for disease resolution. It is notable that 87% of patients in this study required only 1 intervention.
Clinical
Outcome. This long-term cohort study has facilitated detailed stratification of clinical outcome data, although it is difficult to compare these with other publications due to differing diagnostic and clinical decision making, varying treatment protocols and inconsistent terminology seen in other papers 15, 17, 29 . 75% of study patients were, however, DF at census date confirming a degree of treatment efficacy for laser intervention, pertinent because nearly 90% of treated lesions exhibited significant dysplasia. In terms of characterisation, DF patients were generally younger with mild or moderate dysplasia and no LI.
Long term clinic follow-up helped distinguish patients DF after further treatment (34 or 5.8%) from persistent disease despite intervention (53 or 9%). Patients in the Further/DF category were younger, developed new lesions at different sites, had less severe dysplasia and disease resolved after multiple treatments. In contradistinction, Further/Persistent patients were older, commonly had PVL lesions on gingiva, alveolus and labial mucosa and underwent ablation rather than excision. Traditionally, PVL diagnoses were made late during disease history following progressive spread, high recurrence and MT 7, 30 . This study helps emphasise the importance of early PVL recognition in specialist PMD clinics, but recognises that ablative treatment intervention may have reduced efficacy.
6. Malignant Transformation. MT rates for PMDs vary worldwide with quoted values ranging between 0.1 to 40%, and an overall rate estimated at 12%, making it difficult to counsel individual patients 15, 16, 17 . This study distinguished between 71 cases (12%) in which pre-existing OSCCs were discovered upon PMD laser excision and 28 (4.8%) in which OSCC development occurred post-treatment (4.8%). The significance of early OSCC diagnosis is emphasised because all 71 patients were definitively treated by their initial laser intervention. Overall, 80 OSCC cases were identified at the same-site as precursor lesions whilst 19 developed at new sites during follow-up confirming the need for long-term surveillance post-treatment. Recognisable clinico-pathological features associated with MT included an erythroleukoplakic appearance, severe dysplasia or CiS in initial biopsies and floor of mouth/ventro-lateral tongue sites of origin.
7. Study Limitations. This was not a prospective, randomised controlled trial, nor was it multi-centre, and it is recognised that clinician bias may have influenced both patient recruitment and treatment. Reliance on pre-existing clinical records can be problematic because detail and accuracy vary over time. It was disappointing in this study to find incomplete data regarding tobacco and alcohol use during follow-up as these confounding factors may influence outcome. We have, however, previously observed few changes in tobacco and alcohol use in Newcastle PMD patients following treatment 19, 20 . Patient satisfaction and quality of life issues were not assessed in this study; these areas of research are important in modern healthcare provision and will form an integral part of future, prospective studies 31 .
In conclusion, this study has succeeded in providing data on the demographics and clinico-pathological profile of PMD disease in North-East England, and has detailed long-term clinical outcome following intervention. Optimal treatment requires consistent diagnoses, effective intervention and coordinated patient follow-up. Whilst these have been demonstrated in this study cohort, we have not demonstrated reduction in overall cancer risk, although the early identification and treatment of OSCC in 12% of cases probably justifies intervention alone. Whilst further analyses of cases with poor clinical outcome (persistent PMD and MT) are warranted, the next major phase of research requires prospective, multi-centre trialling, ideally internationally, to truly define the efficacy of interventional surgery. 
